While PD-1 serves as a diagnostic biomarker for AITL, a clinical trial of PD1-PDL1 blockade in peripheral T-cell lymphomas (including AITL) was terminated due to high rates of hyperprogression, modest efficacy, and short response durations [40]. This evidence concerns the gene CD274 and peripheral T-cell lymphoma, not otherwise specified.